**Soon-Sun Hong, Ph.D.**

**Professor, College of Medicine, Inha University**

B-308, Jeongsuk Bld., 366 Seohae-daero, Jung-gu, Incheon, 22332, Korea,

hongs@inha.ac.kr

**Education**
**Doctor of Philosophy** (Feb 2001)

Dept. of Pharmaceutics, College of Pharmacy, Seoul National University, Seoul, Korea (Advisor: Chang-Koo Shim)

**Master of Science** (Feb 1998)

Dept. of Pharmaceutics, College of Pharmacy, Seoul National University, Seoul, Korea

**Bachelor of Science** (Feb 1996)

College of Pharmacy, Seoul National University, Seoul, Korea

**Professional Experience**

* 인하대학교 대학원 바이오메디컬 사이언스·엔지니어링 협동과정 전공주임 (2021 - Present)
* BK21 정밀의학 스마트공학 융합 교육연구단 부단장 (2020- Present)
* 인하대학교 대학원 의과학과 전공주임 (2019 - Present)
* 한국연구재단 기초연구본부 성과분석 전문위원 (May 2019 - Present)
* 한국연구재단 의약학단 전문위원 (RB, Nov 2018 - Present)
* 대한암학회 이사 (Jan 2017– Present)
* 미래창조과학부 중견연구자지원사업(도약) 연구책임자 (Nov 2015-Present)
* Inha Fellow Professor (Distinguished Professor), Inha University (2012– 2018)
* Assistant/Associate/Full Professor, School of Medicine, Inha University, Korea (Sep 2007 – Present)
* Senior Scientist, Research Institute of Pharmaceutical Science, Seoul National University, Korea

Advisor: Kyu-Won Kim (May 2003 – Aug 2006)

* Postdoctoral Associate, Yale University School of Medicine, CT, USA

Advisor: Ying Xia (Dec 2001- May 2003)

**Honor/Awards**

**국무총리상 (제 7회 암 예방의 날, 2014.03.21)**

우수 연구상 (인하대학교 의료원, 2020/ 2019 / 2018 / 2011)

**Recent publication** **from 160 SCI Papers.**

ANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis. ***Cancer Letters*** 519: 185-198, 2021

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. ***Cancer Letters*** 507: 97-111, 2021

ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a. ***EMBO Molecular Medicine***. 12(8) e11222, 2020